Spotlight On High Growth Tech Stocks This December 2024

As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Seojin SystemLtd	35.41%	39.86%	★★★★★★
Yggdrazil Group	24.66%	85.53%	★★★★★★
eWeLLLtd	27.24%	28.74%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
Mental Health TechnologiesLtd	24.68%	97.53%	★★★★★★
Medley	25.57%	31.67%	★★★★★★
Fine M-TecLTD	36.23%	131.08%	★★★★★★
Elliptic Laboratories	70.09%	111.37%	★★★★★★
JNTC	29.48%	104.37%	★★★★★★

Click here to see the full list of 1286 stocks from our High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

argenx (ENXTBR:ARGX)

Simply Wall St Growth Rating: ★★★★★★

Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across several regions, including the United States, Japan, Europe, the Middle East, Africa, and China, with a market cap of €35.60 billion.

Operations: The company primarily generates revenue from its biotechnology segment, amounting to $1.91 billion. Its focus is on developing therapies for autoimmune diseases across multiple regions, contributing to its substantial market presence.

Armed with a robust pipeline, argenx is making significant strides in the biotech sector, particularly with its innovative treatments for autoimmune diseases. Recently, the company reported a notable revenue increase to $588.88 million in Q3 2024 from $339.84 million in the previous year, underscoring a growth trajectory with an impressive 55.35% forecasted annual earnings growth rate. Furthermore, argenx's commitment to R&D is evident as it continues to invest heavily; this dedication supports their ongoing Phase 2/3 ALKIVIA study which has shown promising results and met its primary endpoint at Week 24. These developments not only highlight argenx's potential in delivering next-generation therapies but also position it well within the high-growth tech sphere of biotechnology, driven by both scientific innovation and strategic market expansions.

• Take a closer look at argenx's potential here in our health report.

• Learn about argenx's historical performance.

Gentrack Group (NZSE:GTK)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gentrack Group Limited specializes in creating, integrating, and maintaining enterprise billing and customer management software for the energy, water utility, and airport sectors with a market capitalization of approximately NZ$1.46 billion.

Operations: The company's revenue is primarily driven by its utility segment, contributing NZ$181.31 million, followed by the airport segment at NZ$31.93 million. The focus on enterprise billing and customer management software solutions underscores its role in serving essential infrastructure sectors like energy, water utilities, and airports.

Gentrack Group, recently added to the S&P/ASX 300 Index, displayed a solid performance with sales increasing to NZ$213.24 million from NZ$169.88 million last year, though net income slightly dipped to NZ$9.55 million from NZ$10.05 million. This fiscal resilience is underscored by a projected robust annual earnings growth of 29.8%, outpacing the broader New Zealand market's 24.5%. Moreover, the company is aligning with industry trends as its R&D expenses are strategically channeled into enhancing product offerings and capturing emerging market opportunities in tech sectors, signaling potential for sustained growth despite a highly volatile share price in recent months. In terms of innovation and market adaptation, Gentrack's commitment is evident in its R&D investment strategy which supports its forecasted revenue growth of 12.5% annually—faster than New Zealand's average of 4.2%. This strategic focus not only strengthens Gentrack’s position within competitive tech landscapes but also reflects a proactive approach towards leveraging technology advancements to secure long-term profitability and shareholder value amidst dynamic market conditions.

• Delve into the full analysis health report here for a deeper understanding of Gentrack Group.

• Gain insights into Gentrack Group's historical performance by reviewing our past performance report.

Globe-ing (TSE:277A)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Globe-ing Inc. offers DX and strategic consulting, along with digital analytics/data services in Japan, with a market cap of ¥38.84 billion.

Operations: The company generates revenue primarily from data processing services, amounting to ¥4.18 billion.

Following its recent IPO, Globe-ing Inc. has demonstrated strong market entry with a capital raise of ¥4.28 billion, signaling robust investor confidence and substantial financial backing. This influx is poised to bolster their aggressive expansion plans in the tech sector, where they are already outpacing average market growth with a projected annual revenue increase of 48.7% and earnings surge of 82.3%. The company's strategic investment in R&D is crucial, enhancing product innovation and maintaining competitiveness in rapidly evolving technology landscapes—factors that could significantly influence their trajectory in upcoming years.

• Dive into the specifics of Globe-ing here with our thorough health report.

• Review our historical performance report to gain insights into Globe-ing's's past performance.

Taking Advantage

• Delve into our full catalog of 1286 High Growth Tech and AI Stocks here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com